RMX2001, a second-generation oxazolidinone analogue, is a new antibiotic, which is mainly used for the treatment of infections caused by drug-resistant gram-positive bacteria including MRSA (methicillin-resistant staphylococcus aureus), VRE (vancomycin-resistant enterococcus), S. penumonia (streptococcus pneumoniae) and MDR-TB (multidrug-resistant tuberculosis). Because of its unique mechanism of action, it is not easy to cross-resistance with other antibacterial drugs that inhibit protein synthesis, and it is not easy to induce bacterial drug resistance in vitro. Phase II/III clinical trials will be launched in RMX2001.

RMX2001 has stronger activity against gram-positive bacteria in vitro and in vivo, and has excellent pharmacokinetic/pharmacodynamic parameters. meanwhile, RMX2001 has less bone marrow suppression in animal experiments, which shows good curative effect in tuberculosis mouse model. Phase I clinical study on safety, tolerance and pharmacokinetic characteristics of RMX2001, which was completed by Xinwei Medicine, preliminarily showed that RMX2001 had no bone marrow suppression at high dose in the 21-day clinical study.

China is one of the 30 countries with high burden of tuberculosis in the world. Due to the infection of primary drug-resistant bacteria, nonstandard use of drugs in hospitals and nonstandard treatment of patients, tuberculosis is still the second most deadly disease among all legal infectious diseases in China, and the number of drug-resistant bacteria ranks first in the world. At present, drug-resistant tuberculosis in China needs multi-drug treatment for 18 to 24 months, and the cure rate is less than half. According to the domestic epidemiological data, the number of MDR-TB patients has reached about 300,000, and about 100,000 new cases occur every year.